CLYM · Climb Bio, Inc.
AI read · Good for CLYM
The AI's read
The findings give Climb Bio more evidence that CLYM116 can keep its target suppressed for longer, which may allow dosing every 12 weeks. The tests were in healthy volunteers, so they do not show whether the treatment helps people with kidney disease. The ongoing patient trial must answer that, and a Phase 3 study still depends on regulatory feedback.